Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy

G L Banna, R Di Quattro, L Malatino, G Fornarini, A Addeo, M Maruzzo, V Urzia, F Rundo, H Lipari, U De Giorgi, U Basso

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE: To identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibitors (ICIs).METHODS/PATIENTS: We explored the predictive and prognostic values of baseline neutrophil-to-lymphocyte ratio (NLR), with cut-offs ≥ 3 and ≥ 5, and of a urothelial immune prognostic index (UIPI, based on increased NLR and LDH), on 146 patients.RESULTS: NLR and UIPI significantly predicted progressive disease and progression-free survival with both cut-offs (p = 0.0069, p = 0.0034, p = 0.0160, p = 0.0063; p 
Original languageEnglish
Pages (from-to)2130-2135
Number of pages6
JournalClin. Transl. Oncol.
Volume22
Issue number11
DOIs
Publication statusPublished - Nov 2020

Fingerprint Dive into the research topics of 'Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy'. Together they form a unique fingerprint.

Cite this